Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - galantamine hydrobromide, quantity: 30.756 mg (equivalent: galantamine, qty 24 mg) - capsule, modified release - excipient ingredients: iron oxide yellow; microcrystalline cellulose; iron oxide red; gelatin; ethylcellulose; hypromellose; magnesium stearate; titanium dioxide; indigo carmine; erythrosine - galantamine is indicated for the treatment of mild to moderately severe dementia of the alzheimer type

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - galantamine hydrobromide, quantity: 20.504 mg (equivalent: galantamine, qty 16 mg) - capsule, modified release - excipient ingredients: iron oxide red; ethylcellulose; titanium dioxide; hypromellose; gelatin; magnesium stearate; microcrystalline cellulose - galantamine is indicated for the treatment of mild to moderately severe dementia of the alzheimer type

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - galantamine hydrobromide, quantity: 10.252 mg (equivalent: galantamine, qty 8 mg) - capsule, modified release - excipient ingredients: magnesium stearate; ethylcellulose; titanium dioxide; hypromellose; gelatin; microcrystalline cellulose - galantamine is indicated for the treatment of mild to moderately severe dementia of the alzheimer type

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - galantamine hydrobromide, quantity: 30.756 mg (equivalent: galantamine, qty 24 mg) - capsule, modified release - excipient ingredients: iron oxide yellow; microcrystalline cellulose; iron oxide red; gelatin; ethylcellulose; hypromellose; magnesium stearate; titanium dioxide; indigo carmine; erythrosine - galantamine is indicated for the treatment of mild to moderately severe dementia of the alzheimer type

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - galantamine hydrobromide, quantity: 20.504 mg (equivalent: galantamine, qty 16 mg) - capsule, modified release - excipient ingredients: hypromellose; gelatin; ethylcellulose; microcrystalline cellulose; iron oxide red; titanium dioxide; magnesium stearate - galantamine is indicated for the treatment of mild to moderately severe dementia of the alzheimer type

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - galantamine hydrobromide, quantity: 20.504 mg (equivalent: galantamine, qty 16 mg) - capsule, modified release - excipient ingredients: iron oxide red; ethylcellulose; titanium dioxide; hypromellose; gelatin; magnesium stearate; microcrystalline cellulose - galantamine is indicated for the treatment of mild to moderately severe dementia of the alzheimer type

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - galantamine hydrobromide, quantity: 10.252 mg (equivalent: galantamine, qty 8 mg) - capsule, modified release - excipient ingredients: magnesium stearate; gelatin; ethylcellulose; microcrystalline cellulose; titanium dioxide; hypromellose - galantamine is indicated for the treatment of mild to moderately severe dementia of the alzheimer type

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - galantamine hydrobromide, quantity: 30.756 mg (equivalent: galantamine, qty 24 mg) - capsule, modified release - excipient ingredients: iron oxide yellow; hypromellose; magnesium stearate; titanium dioxide; microcrystalline cellulose; iron oxide red; gelatin; ethylcellulose; erythrosine; indigo carmine - galantamine is indicated for the treatment of mild to moderately severe dementia of the alzheimer type

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - galantamine hydrobromide, quantity: 10.252 mg (equivalent: galantamine, qty 8 mg) - capsule, modified release - excipient ingredients: magnesium stearate; ethylcellulose; titanium dioxide; hypromellose; gelatin; microcrystalline cellulose - galantamine is indicated for the treatment of mild to moderately severe dementia of the alzheimer type

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

pharmaten international s.a. industrial park sapes - galantamine (galantamine hydrobromide) - capsules prolonged-release, hard - 8mg